Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.

about

Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.

P2860

Q38764189-4E57D57C-131B-4A09-8DCE-3F2214D39B87 Q55386134-0C32FE52-EA03-434C-B37E-3B1779AA9CE8

P2860

Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.

Item

http://www.wikidata.org/entity/Q51048904

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Safety and efficacy of ruxolit ...... myeloproliferative neoplasms.

@en

Safety and efficacy of ruxolit ...... myeloproliferative neoplasms.

@nl

type

Item

label

Safety and efficacy of ruxolit ...... myeloproliferative neoplasms.

@en

Safety and efficacy of ruxolit ...... myeloproliferative neoplasms.

@nl

prefLabel

Safety and efficacy of ruxolit ...... myeloproliferative neoplasms.

@en

Safety and efficacy of ruxolit ...... myeloproliferative neoplasms.

@nl

P1476

Safety and efficacy of ruxolit ...... h myeloproliferative neoplasms

@en

P2093

Alessandro Castellani

http://www.w3.org/2001/XMLSchema#string

Alessandro M Vannucchi

http://www.w3.org/2001/XMLSchema#string

Alessandro Rambaldi

http://www.w3.org/2001/XMLSchema#string

Arianna Masciulli

http://www.w3.org/2001/XMLSchema#string

Carmela Mannarelli

http://www.w3.org/2001/XMLSchema#string

Chiara Paoli

http://www.w3.org/2001/XMLSchema#string

Elisa Rumi

http://www.w3.org/2001/XMLSchema#string

Fabio Mori

http://www.w3.org/2001/XMLSchema#string

Giovanni Barosi

http://www.w3.org/2001/XMLSchema#string

Giuditta Corbizi Fattori

http://www.w3.org/2001/XMLSchema#string

P2860

Magnetic resonance diffusion-weighted imaging: extraneurological applications.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography.

P304

187-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24614

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27880982

http://www.w3.org/2001/XMLSchema#string

P921

thrombosis

Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.

about

P2860

P2860

Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921